Stock Market Today: Major Indexes Rise Further; S&P 500, Nasdaq Add to Records

U.S. stocks extended gains with the S&P 500 and Nasdaq both setting fresh records, while Trump announced a 10-day ceasefire agreement between Lebanese and Israeli leaders and invited them to the White House for talks. Oil remained elevated despite the ceasefire headlines, with WTI up 3.6% to $94.60 and Brent up 4.5% to $99.20, while the 10-year Treasury yield rose to 4.31% and the dollar index to 98.23. Individual movers included Aehr Test Systems up nearly 15% on a $41 million AI-chip burn-in order, Abbott down 7% on soft guidance, and Hims & Hers up nearly 9% on FDA peptide developments.

Analysis

The market is starting to price a cleaner macro path: lower geopolitical risk, softer energy dislocation, and a quicker return to the Fed’s easing bias. That is supportive for duration-sensitive growth and consumer-discretionary names, but the bigger second-order effect is dispersion: companies with high energy intensity or weak guide rails get punished even in a tape that is otherwise making highs. The near-term setup looks more like leadership rotation than a broad risk-off, because lower oil would mechanically relieve margins for transport, travel, and many industrials, while a sustained $95-$100 crude band keeps headline inflation sticky enough to cap multiple expansion.

The standout winner is anything tied to AI infrastructure and semiconductor test/validation, where capex remains a structural tailwind and short-cycle order flow can re-rate names disproportionately. The Aehr move suggests the market will pay aggressively for bottleneck exposure inside the AI supply chain, especially where customers are qualifying at production scale rather than just piloting. By contrast, TSM’s post-earnings weakness reads less like a demand problem and more like margin skepticism plus an investor preference for names with cleaner operating leverage in the current tape.

Healthcare is showing a classic guidance-over-results failure state: good quarter, but the multiple compresses when the next two quarters are unclear. Abbott’s drawdown likely overstates the fundamental deterioration, but it also signals that defensives with acquisition-related dilution and slower organic growth are not where the market wants to hide if rates remain elevated. Meanwhile, the HIMS move reflects the market assigning option value to regulatory optionality; the trade is less about near-term earnings and more about whether the FDA path meaningfully expands its addressable market.

The most interesting contrarian angle is that the market may be underpricing how fast the ceasefire narrative can unwind. If energy retraces sharply, the beneficiaries of the current inflation shock trade—oil-sensitive cyclicals, cash-heavy defensives, and short-duration value—could give back gains quickly, while rate-cut odds reflate duration assets. Conversely, if the ceasefire proves fragile, today’s equity highs may be a trap: higher oil, higher yields, and weaker consumer sentiment would hit the market’s most crowded leadership names first.

Key Decisions for Investors

• Buy NFLX into the post-print window only on a pullback, with a 1-3 week horizon: the setup is favorable if management confirms ad-tier momentum and resilient churn, but the stock is vulnerable to any ad-spend or margin disappointment after recent index strength.
• Initiate a tactical long HOOD / short regional bank or traditional broker pair for 2-6 weeks: the SEC headline creates a cleaner retail-trading narrative, while the short leg should lag if intraday trading activity rises without a broad risk-off move.
• Fade ABT strength versus EXAS on a 1-2 month horizon: ABT’s guide reset suggests multiple compression can continue, while EXAS has an acquisition-linked strategic catalyst and more room for re-rating if integration risk stays contained.
• Buy AEHR on a momentum-breakout basis but keep it strictly trading-sized: the order win implies real production qualification and could force estimate revisions over the next 1-2 quarters, but the name is extended after a >300% run and will be volatile on any customer-concentration concern.
• Use a barbell hedge: long TSLA calls 2-4 months out against a small short basket of high-energy-exposure travel names (NCLH, RCL) for a crude-price reversal trade; if oil stays elevated, the short leg works, but if energy rolls over the long convexity in TSLA should outperform.